Effects of Extracorporeal Shock Wave Therapy in Cutaneous Microcirculation of Different Wounds
| Registry | NCT02417779 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: single, basic science |
| Enrollment | 240 (Actual) |
| Sponsor | University Hospital Schleswig-Holstein (Other) |
| Conditions | Burn Injury, Acute Wound, Chronic Wound, Burn Scar, Flap Disorder |
| Interventions | Extracorporeal Shock Wave Therapy (Device Name: PiezoWave), Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) (Device) |
| Dates | start 2015-03-01, primary completion 2023-02-01, completion 2023-02-01, first posted 2015-04-16, last updated 2023-02-24 |
| Locations | 1 site in Germany |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Burn Injury All trials for Acute Wound All trials of Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) All trials of Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
In plastic and reconstructive surgery, treatment strategies of second-degree burns, superficial wounds, hypertrophic burn scars, flaps and chronic wounds aim at reducing infection and improving microcirculation. Although previous studies indicate that extracorporeal shock wave therapy (ESWT) can accelerate wound healing, only a few studies focused on the elucidation of its mechanisms of action. Therefore, the aim of this study is to evaluate the microcirculatory effects of extracorporeal shock wave therapy on second-degree burns, superficial wounds, hypertrophic burn scars, flaps and chronic wounds in a human in-vivo setting for the first time.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Second-Degree Burn | Experimental | Device: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body. Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Skin Excision (for Skin Graft) | Experimental | Device: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA. Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Chronic Wound | Experimental | Device: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA. Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Intact Skin | Active comparator | Device: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident. Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Second-Degree Burn (repetitive) | Experimental | Device: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body. Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Skin Excision (for Skin Graft) (repetitive) | Experimental | Device: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA. Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Chronic Wound (repetitive) | Experimental | Device: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA. Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Intact Skin (repetitive) | Active comparator | Device: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident. Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Hypertrophic burn scar | Experimental | Device: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar. Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Hypertrophic burn scar (repetitive) | Experimental | Device: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar. Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Flap | Experimental | Device: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group K (n=20): Consent-capable male and female patients ≥18 years of age who received a flap. Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
| Flap (repetitive) | Experimental | Device: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) | Group L (n=20): Consent-capable male and female patients ≥18 years of age who received a flap. Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave) |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body. * Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA. * Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA. * Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident. No soft tissue injury must be evident. * Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body. * Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA. * Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA. * Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups E-G must be evident. No soft tissue injury must be evident. * Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar. * Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar. * Group K (n=20): Consent-capable male and female patients ≥18 years of age who received a flap. * Group L (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.. Exclusion Criteria: General exclusion criteria * below 18 years of age * wounds requiring artificial respiration, since consent for the study participation is unobtainable Exclusion Criteria Groups A, B, D, E, F, H: * peripheral arterial occlusive disease * vasculitis * diabetes mellitus * chronic kidney or liver disease * cardiac dysfunction * arterial hypo- or hypertension Anamnestic exclusion criteria * ongoing immunosuppressive or chemotherapy treatment * drug abuse * systemic skin diseases * systemic and local cortisone therapy
| Facility | City | Country | Status |
|---|---|---|---|
| University of Schleswig-Holstein | Lübeck, Schleswig-Holstein | Germany |